Cardiac Biotech Solutions (OTCMKTS:CBSC) is a biotechnology company dedicated to developing and commercializing advanced cell-based therapies for the treatment of cardiovascular diseases. The company’s core focus lies in harnessing the regenerative potential of mesenchymal stromal cells (MSCs) and exosome-derived products to address unmet clinical needs in acute myocardial infarction, chronic heart failure and peripheral vascular disorders. Leveraging proprietary cell culture and preservation technologies, Cardiac Biotech Solutions aims to deliver off-the-shelf therapeutic products that support tissue repair, modulate inflammation and promote angiogenesis in damaged cardiac tissue.
Founded in 2004 as a spin-out from a leading academic research institution, Cardiac Biotech Solutions has built a vertically integrated platform that encompasses preclinical research, process development, manufacturing and quality assurance. The company’s manufacturing facility, which operates under current Good Manufacturing Practice (cGMP) standards, enables scalable production of allogeneic cell therapies and exosome formulations. In addition, Cardiac Biotech Solutions provides cryopreservation and shipping services designed to maintain product viability and potency through complex supply chains, ensuring consistent delivery to clinical trial sites and strategic partners.
Cardiac Biotech Solutions has established scientific collaborations and licensing agreements with major medical centers and biotechnology firms across North America and Europe. These partnerships support multi-center clinical trials as well as research into novel indications, including peripheral artery disease and diabetic cardiomyopathy. The company’s research team is led by Chief Scientific Officer Dr. Emily Chen, whose work in myocardial regeneration has been published in prominent peer-reviewed journals. Cardiac Biotech Solutions also maintains an advisory board of cardiologists, immunologists and regulatory experts to guide product development and clinical strategy.
Under the leadership of President and CEO Dr. Jane Doe, a veteran biotech executive with over 20 years of experience in cell therapy and regenerative medicine, Cardiac Biotech Solutions is positioned to advance its clinical pipeline and expand its commercial footprint. The company continues to invest in manufacturing capacity, quality systems and strategic alliances to support the upcoming Phase II studies for its lead MSC-based therapy. With a commitment to innovation and patient outcomes, Cardiac Biotech Solutions seeks to establish new standards for regenerative treatment of cardiovascular disease worldwide.
AI Generated. May Contain Errors.
